Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Regor will receive $850 million upfront, a hefty amount for two Phase I candidates.